jiadifenin: seco-prezizaane-type sesquiterpene with neurotrophic activity from Illicium jiadifengpi; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Illicium | genus | A plant genus of the family SCHISANDRACEAE, order AUSTROBAILEYALES, class MAGNOLIOPSIDA. They have evergreen, aromatic leaves and bisexual flowers. The female portion of the flower consists of 7 to 15 carpels.[MeSH] | Schisandraceae | A plant family of the order AUSTROBAILEYALES, class MAGNOLIOPSIDA.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 11544617 |
| CHEMBL ID | 465570 |
| MeSH ID | M0428849 |
| Synonym |
|---|
| jiadifenin |
| CHEMBL465570 |
| methyl (1r,2r,6r,10r,11r)-10,13-dihydroxy-2,6-dimethyl-3,9-dioxo-8,12-dioxatetracyclo[9.2.1.01,5.06,10]tetradec-4-ene-13-carboxylate |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID334220 | Neurotrophic activity in Sprague-Dawley rat neurons assessed as induction of neurite outgrowth at 0.1 to 10 uM after 5 days by microscopy | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | New seco-prezizaane-type sesquiterpenes, jiadifenin with neurotrophic activity and 1,2-dehydroneomajucin from Illicium jiadifengpi. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||